
OBSVF
Healthcare · Biotechnology
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 17, 2023 | Time not confirmed | -0.06 | 0.33 | +658.2% |
| Mar 31, 2023 | After the close | -0.08 | 0.25 | +412.5% |
| Dec 1, 2022 | After the close | -0.08 | -0.13 | -62.5% |
| Aug 17, 2022 | After the close | -0.17 | -0.39 | -129.4% |
| May 16, 2022 | After the close | -0.20 | -0.14 | +30.0% |
| Mar 9, 2022 | After the close | -0.22 | -0.26 | -18.2% |
| Nov 3, 2021 | After the close | -0.22 | 0.01 | +104.5% |
| Aug 4, 2021 | After the close | -0.25 | -0.25 | 0.0% |
| May 5, 2021 | After the close | -0.28 | -0.29 | -3.6% |
| Mar 4, 2021 | After the close | -0.42 | -0.32 | +23.8% |
| Nov 4, 2020 | After the close | -0.34 | -0.49 | -44.1% |
| Aug 5, 2020 | After the close | -0.42 | -0.38 | +9.5% |
| May 5, 2020 | Time not confirmed | -0.48 |
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
| -0.48 |
| 0.0% |
| Mar 4, 2020 | After the close | -0.58 | -0.48 | +17.2% |
| Nov 6, 2019 | After the close | -0.82 | -0.63 | +23.2% |
| Aug 6, 2019 | After the close | -0.60 | -0.80 | -33.3% |
| May 8, 2019 | After the close | -0.51 | -0.59 | -15.7% |
| Mar 4, 2019 | After the close | -0.49 | -0.46 | +6.1% |
| Nov 7, 2018 | After the close | -0.46 | -0.42 | +8.7% |
| Aug 7, 2018 | After the close | -0.53 | -0.49 | +7.5% |
| May 16, 2018 | Before the open | -0.47 | -0.54 | -14.9% |
| Mar 9, 2018 | Before the open | -0.56 | -0.48 | +14.3% |